List of Excipients in Branded Drug SIGNATURE CARE ACID CONTROL

Generic Drugs Containing SIGNATURE CARE ACID CONTROL

Company	Ingredient	NDC	Excipient
Safeway	ranitidine	21130-116	CELLULOSE, MICROCRYSTALLINE
Safeway	ranitidine	21130-116	D&C YELLOW NO. 10
Safeway	ranitidine	21130-116	FD&C BLUE NO. 2
Safeway	ranitidine	21130-116	FD&C RED NO. 40
Safeway	ranitidine	21130-116	HYPROMELLOSES

What are the Most Frequently-Used Excipients in SIGNATURE CARE ACID CONTROL?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
2	FD&C BLUE NO. 2
1	FD&C RED NO. 40

Signature Care Acid Control Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Signature Care Acid Control is a private-label over-the-counter acid reducer built around famotidine, typically in 10 mg or 20 mg immediate-release tablets. Its commercial position depends less on active-ingredient exclusivity than on low-cost tableting, acceptable consumer experience, packaging differentiation, retailer economics, and reliable supply. The strongest opportunities are line extensions using the same famotidine platform, including chewable, orally disintegrating, dual-action, and condition-specific products.

What is Signature Care Acid Control?

Signature Care Acid Control is a retailer-branded famotidine product sold through the Signature Care private-label portfolio. The principal reference product is Pepcid AC, marketed by Kenvue in the United States. Signature Care products are generally positioned as lower-priced alternatives for heartburn, acid indigestion, and sour stomach.

Product attribute	Commercial assessment
Brand	Signature Care
Therapeutic category	OTC acid reducer
Active ingredient	Famotidine
Common strengths	10 mg and 20 mg
Dosage form	Immediate-release oral tablet; product-specific variants may differ
Reference brand	Pepcid AC
Mechanism	Histamine-2 receptor antagonist
Primary use	Relief and prevention of heartburn
Regulatory pathway	OTC nonprescription drug
Primary commercial channel	Mass retail, pharmacy, grocery, and e-commerce
Likely purchaser	Retailer or private-label marketing organization
Key competitive factor	Retail price and availability

Famotidine suppresses gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells. It does not neutralize acid in the same way as calcium carbonate or magnesium hydroxide antacids. The distinction supports combination products that pair rapid acid neutralization with longer-duration acid suppression.

What excipients are used in Signature Care Acid Control?

The exact inactive-ingredient profile depends on the specific national drug code, strength, dosage form, manufacturer, and coating configuration. Typical famotidine immediate-release tablets use excipients from the following functional groups:

Excipient function	Typical materials	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, starch, dibasic calcium phosphate	Adds tablet mass and supports compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Controls tablet breakup and drug release
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose	Provides coating integrity
Plasticizer	Polyethylene glycol	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, approved lake colors	Controls appearance and product identification
Sweetener or flavor	Product-dependent	Supports chewable or orally disintegrating formats

A cost-efficient formulation should use a conventional direct-compression or dry-granulation process unless famotidine flow, blend uniformity, or segregation requires additional processing. The formulation objective is not maximum excipient sophistication. It is consistent low-dose content uniformity, rapid disintegration, acceptable swallowability, stable appearance, and low manufacturing cost.

Which excipients matter most for famotidine tablets?

Content uniformity is a primary technical issue because a 10 mg or 20 mg dose represents a relatively small fraction of total tablet weight. Poor powder flow or segregation can create potency variation. Microcrystalline cellulose, colloidal silicon dioxide, and a controlled lubrication system can improve blend behavior, but excessive lubricant can slow dissolution.

Disintegrant selection directly affects consumer perception. Crospovidone may support rapid breakup with relatively low viscosity. Croscarmellose sodium can provide strong swelling and wicking. Sodium starch glycolate may be attractive in cost-sensitive formulations but requires control of concentration and granule structure.

The coating system affects appearance, moisture protection, swallowability, and line efficiency. A thin hypromellose-based film can support private-label differentiation without materially increasing unit cost. Excessive coating weight can slow disintegration and increase batch time.

How should the excipient strategy be optimized?

The most effective base formulation is a small, robust excipient platform that can support multiple strengths and pack sizes. The same core blend should ideally cover 10 mg and 20 mg strengths, with dose adjustment through active-ingredient loading or tablet weight rather than a completely different manufacturing process.

Recommended base-platform strategy

1. Use direct compression where flow and content uniformity are demonstrated.
2. Use microcrystalline cellulose or dibasic calcium phosphate as the principal filler.
3. Select one high-performance disintegrant and validate rapid release across the stability program.
4. Keep magnesium stearate concentration and blending time tightly controlled.
5. Use a low-weight film coat to reduce coating cost and improve brand recognition.
6. Avoid unnecessary excipients that create allergen, labeling, supply, or regulatory complexity.
7. Qualify at least two suppliers for critical excipients and packaging materials.
8. Maintain a common formulation architecture across tablet strengths.

For a retailer brand, excipient simplicity has commercial value. It reduces change-control burden, improves manufacturing transfer, and permits sourcing from multiple contract manufacturers. The formulation should avoid dependence on a single proprietary excipient unless that material provides a clear advantage in taste, disintegration, or manufacturability.

What formulation patents protect Signature Care Acid Control?

The core famotidine tablet is unlikely to have meaningful composition-of-matter protection. Famotidine was discovered decades ago, and the original small-molecule patent estate is expired. A conventional immediate-release generic tablet generally faces limited patent risk if it does not copy a protected branded formulation, delivery system, or method of use.

Potentially relevant rights may cover:

• Chewable or orally disintegrating dosage forms
• Taste-masking systems
• Dual-action combinations containing famotidine and an antacid
• Modified-release delivery
• Specific excipient ratios
• Manufacturing processes
• Packaging systems
• Pediatric dosing formats
• Consumer-use instructions or method-of-use claims

These rights would generally be product-specific rather than inherent to all famotidine tablets. A private-label manufacturer can reduce risk by using an independent formulation, avoiding unnecessary similarity to Pepcid AC in tablet appearance or packaging, and conducting a freedom-to-operate review before launching a differentiated format.

When does Signature Care Acid Control lose exclusivity?

Signature Care Acid Control does not appear to have standalone drug exclusivity comparable to a new prescription product. Famotidine is an established active ingredient sold through multiple generic and private-label channels.

Exclusivity category	Assessment
New chemical entity exclusivity	Not applicable
New drug product exclusivity	Not applicable to the established OTC product
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Prescription generic exclusivity	Not applicable to the OTC retail product
Core active-ingredient patent	Expired
Product-specific formulation rights	Possible, depending on the SKU
Retail private-label advantage	Based on sourcing, price, placement, and retailer relationship

The commercial risk is therefore substitution, not a scheduled patent cliff. A competing retailer can source a similar famotidine tablet from another contract manufacturer, subject to FDA requirements and applicable intellectual-property constraints.

What is the FDA regulatory status of Signature Care Acid Control?

Famotidine is an FDA-recognized OTC acid reducer. OTC products must comply with the applicable FDA monograph conditions or obtain approval through another lawful pathway. The Drug Facts label must identify the active ingredient, purpose, uses, warnings, directions, inactive ingredients, and other required information under FDA labeling rules.[1][2]

An OTC famotidine product must control:

• Active-ingredient identity and strength
• Tablet weight and content uniformity
• Dissolution and disintegration
• Assay and degradation products
• Microbiological quality
• Stability through labeled shelf life
• Packaging and tamper evidence
• Drug Facts labeling
• Manufacturing under current good manufacturing practice

Unlike prescription generic products, an OTC monograph product does not normally rely on an abbreviated new drug application for the same commercial launch model. The regulatory strategy is closely linked to compliance with the applicable OTC requirements and the product’s labeling and formulation.

Does Signature Care Acid Control face Paragraph IV challenges?

Paragraph IV litigation is generally an abbreviated new drug application issue. A conventional OTC famotidine private-label product is not typically exposed to the same Paragraph IV process as a prescription generic seeking approval against a listed prescription drug.

Risk can arise if a company changes the product into a formulation that depends on an approved drug application, patented delivery technology, or a branded combination product. For the standard immediate-release tablet, the principal legal checks are formulation patent clearance, labeling compliance, trademark clearance, trade-dress risk, and manufacturing qualification.

What commercial opportunities exist for excipient-led product extensions?

Chewable famotidine tablets

Chewable tablets can improve convenience for consumers who want rapid use without water. The formulation challenge is taste. Famotidine can require flavor masking, sweetener optimization, and mouthfeel control. Polyols such as mannitol may provide cooling sensation and improved compressibility, but they can increase tablet size and create gastrointestinal tolerance considerations at high loads.

A successful chewable product can command a higher retail price than a standard tablet while using the same active ingredient. The principal barriers are taste, friability, moisture sensitivity, and consumer acceptance.

Orally disintegrating tablets

An orally disintegrating tablet can create a portability and convenience position. Crospovidone, mannitol, microcrystalline cellulose, and porous processing aids can support rapid disintegration. Packaging must protect against moisture and mechanical damage.

This format has a stronger differentiation opportunity than a standard film-coated tablet, but it also carries higher packaging and manufacturing costs.

Dual-action acid relief

A combination of famotidine with an antacid can address both rapid symptom relief and longer acid suppression. Calcium carbonate, magnesium hydroxide, or magnesium carbonate may be considered depending on regulatory and formulation requirements.

The key technical risks are chemical compatibility, moisture management, tablet size, dissolution behavior, and label complexity. Combination products also increase raw-material count and may create more stringent stability and process-control requirements.

Sugar-free and low-allergen positioning

Sugar-free, lactose-free, and gluten-free claims can expand consumer reach if supported by formulation controls and appropriate labeling. These claims are useful in retailer segmentation, especially for e-commerce search and pharmacy planograms.

Excipient selection must account for cross-contact controls, supplier documentation, and label accuracy. A claim can increase commercial value only if the supply chain can maintain it consistently.

Pediatric and family formats

Lower-strength products, chewables, and smaller tablets can support family-oriented packaging. Pediatric use requires careful labeling and dosing controls. The commercial opportunity is meaningful, but it carries higher regulatory and safety sensitivity than an adult 20 mg tablet.

How does Signature Care Acid Control compare with Pepcid AC and antacids?

Attribute	Signature Care Acid Control	Pepcid AC	Calcium carbonate antacid
Active ingredient	Famotidine	Famotidine	Calcium carbonate
Drug class	H2 receptor antagonist	H2 receptor antagonist	Antacid
Typical onset	Slower than an immediate neutralizer	Similar active-ingredient profile	Usually rapid
Duration	Longer acid suppression than a single-dose antacid	Comparable to famotidine products	Often shorter
Differentiation	Price, pack size, retailer access	Brand recognition and marketing	Speed, familiarity, chewable formats
Patent exposure	Low for conventional tablet	Product-specific rights may apply	Generally low for conventional products
Excipient opportunity	High in private-label line extensions	Brand-led formulation and packaging	Flavor, chewability, mineral balance

Signature Care’s principal advantage is price. Pepcid AC retains advantages in brand recognition, consumer trust, and promotional reach. Calcium carbonate products compete for consumers prioritizing immediate relief and chewable administration.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate. Famotidine tablets use established pharmaceutical processes, and multiple contract manufacturers can potentially produce them. The more material barriers are:

• Reliable low-dose blend uniformity
• Stable supply of active pharmaceutical ingredient
• Tablet hardness without delayed disintegration
• Coating efficiency
• Moisture control
• Packaging availability
• Compliance with OTC labeling and cGMP requirements

Intellectual-property barriers rise with product differentiation. A conventional tablet has a lower risk profile than a taste-masked chewable, orally disintegrating product, or dual-action combination. Packaging and trade dress also require review because private-label products can unintentionally resemble branded products too closely.

Which companies challenge Signature Care Acid Control?

The relevant competitors are generic and private-label suppliers rather than named prescription challengers. Major competitive groups include:

• Kenvue through Pepcid AC
• Perrigo and other private-label OTC manufacturers
• Retailer-owned pharmacy brands
• Amazon and e-commerce private labels
• Generic-drug manufacturers distributing famotidine tablets
• Antacid manufacturers selling calcium carbonate or combination products

Supplier concentration can change by SKU and retailer contract. The commercial buyer should evaluate approved manufacturing sites, FDA inspection history, shortage exposure, raw-material qualification, and recall history before awarding volume.

What is the revenue exposure and launch opportunity?

Signature Care does not publicly report standalone revenue for Acid Control. The product’s economic value is best assessed through retail sell-through, gross margin, unit velocity, promotional lift, and repeat purchase rather than reported brand revenue.

The strongest launch scenarios are:

Launch concept	Revenue potential	Cost profile	Main risk
Standard 20 mg tablet	High volume, low margin	Low	Commodity price competition
10 mg tablet	Moderate volume	Low	Limited differentiation
Chewable tablet	Moderate to high	Medium	Taste and tablet size
Orally disintegrating tablet	Moderate	Medium to high	Moisture and packaging
Famotidine-antacid combination	High potential	Medium to high	Compatibility and regulatory complexity
Sugar-free family pack	Moderate	Low to medium	Claim and supply-chain control

A retailer can improve economics through larger count bottles, multipacks, seasonal placement, online subscriptions, and coordinated gastrointestinal-care assortments. Excipient changes should support a visible consumer benefit or measurable manufacturing saving. Invisible formulation complexity rarely justifies a premium.

Key Takeaways

• Signature Care Acid Control is a private-label famotidine OTC product, commonly sold as a 10 mg or 20 mg immediate-release tablet.
• The conventional tablet has low core patent risk because famotidine is an established active ingredient with expired original protection.
• Excipient strategy should prioritize content uniformity, rapid disintegration, coating efficiency, low tablet cost, and supply-chain flexibility.
• Chewable, orally disintegrating, and dual-action products offer the clearest commercial opportunities.
• Taste masking, moisture control, combination-product compatibility, and packaging are the main technical barriers to differentiated products.
• Standard tablets compete primarily on price and availability against Pepcid AC and other generic or private-label products.
• Signature Care’s standalone revenue is not publicly disclosed; retailer sell-through and margin data are the appropriate commercial measures.
• Paragraph IV risk is limited for a conventional OTC tablet but can increase for patented formulations, combinations, delivery systems, or products relying on approved application-specific rights.

FAQs

Can Signature Care Acid Control use the same excipients as Pepcid AC?

It can use common pharmaceutical excipients if the resulting formulation complies with FDA requirements and does not infringe formulation or manufacturing claims. Matching the branded product’s inactive-ingredient profile is not necessary and can increase trade-dress or freedom-to-operate concerns.

Is famotidine compatible with calcium carbonate in a combination tablet?

A combination is technically feasible, but compatibility, tablet size, moisture exposure, dissolution, assay, and stability require product-specific development. Calcium carbonate can materially change compression behavior and formulation weight.

Does a chewable famotidine product justify a higher retail price?

It can, if taste, texture, portability, and onset expectations create a clear consumer benefit. The premium must offset higher flavoring, compression, coating, packaging, and stability costs.

Which excipient is most important for famotidine tablet performance?

No single excipient controls the entire product. The most important system is the interaction among the diluent, disintegrant, glidant, lubricant, and coating. Content uniformity and dissolution should drive selection.

Can Signature Care Acid Control be reformulated without a new patent strategy?

A routine excipient substitution may not need new patent protection, but a differentiated formulation can create protectable trade secrets or patent opportunities. Any new chewable, orally disintegrating, combination, or modified-release product requires a separate freedom-to-operate and regulatory assessment.

References

1. U.S. Food and Drug Administration. (2023). OTC monograph drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines/otc-monograph-drug-products
2. U.S. Food and Drug Administration. (2024). Drug facts label. https://www.fda.gov/drugs/understanding-over-counter-medicines/drug-facts-label
3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. National Library of Medicine. (2024). DailyMed. https://dailymed.nlm.nih.gov/dailymed/
5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm